Boston Scientific's Cyber Wounds Run Deeper Than One Quarter — Can Investors Trust the Recovery Timeline?

Shares plunged 11.2% to $40.00 as Boston Scientific's October 28 earnings report confirmed what the market feared: an August cyberattack didn't just dent one quarter — it dragged down the entire year. The company reported $5.138 billion in third-quarter sales, growing just 1.5% year over year , a dramatic deceleration from Q2's $5.44 billion and 7.5% growth . The question now is whether this is a one-year setback or the start of a longer slump.

• A Cyberattack Knocked Out the Factory Floor — and the Numbers Show It. On August 25, unauthorized activity caused a global network outage that cut off manufacturing, order processing, and shipping.

Wells Fargo estimated the roughly eight days of downtime cost about $300 million in Q3 sales and $0.13 per share in earnings.

GAAP net income fell to $582 million from $755 million a year ago , a 23% decline that shows how quickly fixed costs eat into profit when revenue stalls.

• Full-Year Guidance Took a Second Hit — and Q4 Looks Worse. Boston Scientific now expects fourth-quarter sales to decline 1% to 3% , an unusual contraction for a company that had been guiding for high-single-digit annual growth earlier this year. Before the attack, the company had targeted full-year organic growth of 5% to 6% and adjusted EPS of $3.28 to $3.32 ; now the EPS outlook sits at roughly $3.16–$3.18, a cut of about 4%. This isn't just cyber math — slower demand for its heart-implant device and competitive losses in its electrical-pulse heart treatment business were already weakening the outlook before the hack.

• The Stock Has Been Cut in Half, Yet the Recovery Is Years Away. Boston Scientific's one-year total shareholder return has declined 54.8% , and management's own messaging pushes a product-driven recovery to 2028.

A restructuring program targeting about $500 million in annual cost savings won't fully materialize until end of 2029. That's a long time to ask shareholders to wait.

• Wall Street Sees a Firewall Between 2026 and the Long-Term Story. Wells Fargo made no changes to its growth estimates for 2027 and beyond , and Boston Scientific itself has said the cyber incident won't materially affect its long-term financial condition. But at $40, investors are pricing in skepticism — the company must prove it can ship normally, recapture deferred orders, and stabilize competitive share before that longer-term thesis matters.